1-20 of 67
Steven I. Park
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601

Steven I. Park, Stephen M. Ansell, Danielle Boselli, Sharmila Giri, Jakub Svoboda, Stephen D Smith, Tatyana Feldman, L. Elizabeth Budde, Andrew J Ness, Philip Bierman, Hun Ju Lee
Journal: Blood
Blood (2024) 144 (Supplement 1): 458.
https://doi.org/10.1182/blood-2024-202207
Published: 2024
Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Brittany Knick Ragon, Manisha Bhutani, Barry Paul, Yifan Pang, Cindy Varga, Srinivasa Reddy Sanikommu, Bei Hu, Ryan Jacobs, Tamara K Moyo, Shebli Atrash, Christopher J Ferreri, Steven I. Park, David M Foureau, Nilanjan Ghosh, Peter M. Voorhees, Ariel Bell, Phillip Holmes-Snowden, Olga Better, Nury M. Steuerwald, Wei Sha, Lawrence J. Druhan, Michael R. Grunwald
Journal: Blood
Blood (2024) 144 (Supplement 1): 2669.
https://doi.org/10.1182/blood-2024-200958
Published: 2024
Journal Articles

CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma

David M Foureau, Fei Guo, Erik Broemsen, Tahj Jones, Anna Ivanina-Foureau, Ryan Jacobs, Bei Hu, Tamara K Moyo, Yifan Pang, Steven I. Park, Lawrence J. Druhan, Ariel Bell, Nilanjan Ghosh
Journal: Blood
Blood (2024) 144 (Supplement 1): 2053.
https://doi.org/10.1182/blood-2024-205720
Published: 2024
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David J Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Yingxue Chen, Jade Chen, Rajat Bannerji, Apoorva Kapopara, Attila Szanto, Franck Morschhauser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3035.
https://doi.org/10.1182/blood-2023-179910
Published: 2023
Journal Articles

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

David M Foureau, Hamid Ehsan, Fei Guo, Tahj Jones, Ryan W Jacobs, Bei Hu, Tamara K. Moyo, Yifan Pang, Steven I. Park, Lawrence J. Druhan, Ariel Bell, Nilanjan Ghosh
Journal: Blood
Blood (2023) 142 (Supplement 1): 1640.
https://doi.org/10.1182/blood-2023-187085
Published: 2023
Journal Articles

Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T-Cell (CART) Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

Hamid Ehsan, Ferdous Ahmed, Tamara K. Moyo, Bei Hu, Ryan W Jacobs, Yifan Pang, Steven I. Park, Vishal Shroff, Victoria Boseman, Travis Beam, Jennifer Elder, Nilanjan Ghosh
Journal: Blood
Blood (2023) 142 (Supplement 1): 7393.
https://doi.org/10.1182/blood-2023-186984
Published: 2023
Journal Articles

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma

Steven I. Park, Lakshmi Nayak, Danielle Boselli, Raphael E Steiner, Ashley L Sumrall, Nazanin K Majd, Xhevahire Begic, Sarah Norek, Christopher Dittus
Journal: Blood
Blood (2023) 142 (Supplement 1): 1723.
https://doi.org/10.1182/blood-2023-179526
Published: 2023
Journal Articles

MYC Pathway Upregulation Identified in Non-Responders to Hypomethylating Agents and Presents a Therapeutic Target in Acute Myeloid Leukemia

Brittany Knick Ragon, Margaret D. Templeton, Sara L. Seegers, Jenny Chen, Hsih-Te Yang, Thomas G. Knight, Jing Ai, Edward A. Copelan, Belinda Avalos, Nury M. Steuerwald, Jian Jin, Gang Greg Wang, Steven I. Park, Jai N. Patel, Michael R. Grunwald, Lawrence J. Druhan
Journal: Blood
Blood (2023) 142 (Supplement 1): 5741.
https://doi.org/10.1182/blood-2023-179318
Published: 2023
Journal Articles

Heterodimerization of CSF3R Splice Variants and Mutants Alter Receptor Function

Sara L. Seegers, Amanda Lance, Steven I. Park, Belinda R. Avalos, Lawrence J Druhan
Journal: Blood
Blood (2022) 140 (Supplement 1): 5465–5466.
https://doi.org/10.1182/blood-2022-170480
Published: 2022
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Connie Lee Batlevi, Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Manu Sondhi, Yingxue Chen, Pamela L. Slatcher, Richard Lin, Attila Szanto, Sara Abbadi, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 2296–2298.
https://doi.org/10.1182/blood-2022-166991
Published: 2022
Journal Articles

Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Steven I. Park, Stephen M. Ansell, Sharmila Giri, Jakub Svoboda, Stephen D Smith, Tatyana Feldman, Elizabeth L. Budde, Andrew J Ness, Yunsik Choi, Philip J Bierman, Hun Ju Lee
Journal: Blood
Blood (2022) 140 (Supplement 1): 1751–1752.
https://doi.org/10.1182/blood-2022-159258
Published: 2022
Journal Articles

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

Timothy J. Voorhees, Anne W. Beaven, Christopher Dittus, George E Hucks, J. Kaitlin Morrison, Catherine Joyce Arago Cheng, Tammy Cavallo, Steven I. Park, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo, Natalie S. Grover
Journal: Blood
Blood (2022) 140 (Supplement 1): 12723–12724.
https://doi.org/10.1182/blood-2022-156660
Published: 2022
Journal Articles

Aurora Kinase Inhibition Overcomes Primary Venetoclax Failure and Leads to Synthetic Lethality in BCL2-Positive Lymphomas Via Upregulation of P53/P21/BAX Axis

Rajeswaran Mani, Samon Benrashid, Sarah E Teague, Scott C Jaros, Hsih-Te Yang, Lawrence J Druhan, David M Foureau, Nury M Steuerwald, Nilanjan Ghosh, Edward A. Copelan, Donald L. Durden, Belinda Avalos, Steven I. Park
Journal: Blood
Blood (2021) 138 (Supplement 1): 682.
https://doi.org/10.1182/blood-2021-146064
Published: 2021
Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser
Journal: Blood
Blood (2021) 138 (Supplement 1): 2207.
https://doi.org/10.1182/blood-2021-148199
Published: 2021
Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2488.
https://doi.org/10.1182/blood-2021-152225
Published: 2021
Journal Articles

A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus

Christopher Dittus, Natalie S Grover, Tarsheen Sethi, Jonathon B. Cohen, Alfredo Voloschin, Janhvi Rabadey, Xianming Tan, Anne W. Beaven, Steven I. Park
Journal: Blood
Blood (2021) 138 (Supplement 1): 1457.
https://doi.org/10.1182/blood-2021-145133
Published: 2021
Journal Articles

Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

Ashley Matuszfisher, Rupali Bose, Danielle Boselli, Gray Magee, Tommy Chen, Bei Hu, Tamara K. Moyo, Amy Soni, Steven I. Park, Edward A. Copelan, Belinda Avalos, James T Symanowski, Derek Raghavan, Ryan Jacobs, Nilanjan Ghosh
Journal: Blood
Blood (2021) 138 (Supplement 1): 1557.
https://doi.org/10.1182/blood-2021-145714
Published: 2021
Journal Articles

The Novel Multitarget Small-Molecule Inhibitor SRX3177 Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma

Dhananjaya Pal, Cody C. McHale, Samon Benrashid, Poornima Gourabathini, Krishnaiah Maddeboina, Kendra R. Vann, Rajeswaran Mani, Tatiana Kutateladze, Peter Martin, Maurizio Di Liberto, Selina Chen-Kiang, Steven I. Park, Donald L. Durden
Journal: Blood
Blood (2021) 138 (Supplement 1): 2262.
https://doi.org/10.1182/blood-2021-154253
Published: 2021
Journal Articles

Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Jonathon B. Cohen, MDMS, Jeffrey M. Switchenko, PhD MS, Krithika Shanmugasundaram, MD, Subir Goyal, Oscar Calzada, BS, Michael C. Churnetski, Bhaskar Kolla, MBBS, Veronika Bachanova, MD PhD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Max J. Gordon, MD, Alexey Danilov, MD PhD, Natalie S Grover, MD, Stephanie Mathews, MD, Madelyn Burkart, MD, Reem Karmali, MD, Yazeed Sawalha, MD, Brian T. Hill, MD, Nilanjan Ghosh, MD PhD, Steven I Park, MD, Narendranath Epperla, MDMS, David A. Bond, MD, Talha Badar, MD, Kristie A. Blum, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Mary-Kate Malecek, MD, Peter Martin, FRCPC, MD MS, Jin Guo, MD, Christopher R. Flowers, MD MS, Brad S. Kahl, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3483.
https://doi.org/10.1182/blood-2019-128864
Published: 2019
Journal Articles

Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed

Bei Hu, MD, Tommy Chen, Danielle Boselli, MS, Rupali Bose, MS, MBA, James T. Symanowski, PhD, Derek Raghavan, MDPhDFACP,FRACP, Amy Soni, MD, Steven I Park, MD, Belinda R Avalos, MD, Edward A Copelan, Ryan Jacobs, MD, Nilanjan Ghosh, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 425.
https://doi.org/10.1182/blood-2019-123998
Published: 2019